V1RJ3 Inhibitors
V1RJ3 inhibitors are a class of chemical compounds that interact with a specific biological target identified by the alphanumeric code V1RJ3. This code typically could represent a particular receptor, enzyme, ion channel, or other protein that plays a critical role in certain biochemical pathways within organisms. Inhibitors, by definition, are molecules that can bind to their targets with high affinity and specificity, leading to a decrease in the target's activity. The interaction between V1RJ3 inhibitors and their target is governed by the principles of molecular recognition, which is driven by various noncovalent interactions such as hydrogen bonding, hydrophobic forces, van der Waals interactions, and sometimes even transient covalent bonds.
The molecular architecture of V1RJ3 inhibitors is usually characterized by a precise arrangement of atoms that allows them to fit into the active site or a binding region of the V1RJ3 target. The design of these inhibitors often relies on a deep understanding of the target's structure and the key amino acids or other residues that are crucial for its function. Advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and cryo-electron microscopy contribute to elucidating the target's three-dimensional structure, enabling the rational design of inhibitors. The inhibitors might mimic the natural substrate or ligand of the V1RJ3 target, competing for binding, or they could bind to allosteric sites that induce conformational changes, which in turn modulate the activity of the target. The specificity and potency of these inhibitors depend not only on their ability to bind to the target but also on their pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, which influence their overall behavior in the biological system where the target is present.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor that can reduce the activity of EGFR-dependent signaling pathways. As V1RJ3 may be influenced by downstream effects of EGFR signaling, inhibition of EGFR could indirectly lead to reduced V1RJ3 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that dampens the PI3K/AKT/mTOR signaling cascade. Since V1RJ3 function could be associated with this pathway through downstream effects, the inhibition of mTOR by rapamycin could indirectly decrease V1RJ3 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that disrupts the PI3K/AKT signaling pathway. Given that V1RJ3 activity may be modulated by this pathway, the use of LY294002 could lead to an indirect inhibition of V1RJ3. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that interferes with the MAPK/ERK pathway. Since V1RJ3 might be regulated by the MAPK/ERK pathway, inhibiting MEK with U0126 could indirectly lead to a decrease in V1RJ3 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could reduce the activity of the p38 MAPK signaling pathway. If V1RJ3 is connected to this pathway, the inhibition by SB203580 could result in decreased V1RJ3 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, and by curtailing PI3K activity, it can lead to reduced AKT signaling. This inhibition could indirectly affect V1RJ3 if it is involved in the AKT pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src kinase inhibitor that can inhibit multiple tyrosine kinases. Should V1RJ3 be linked to Src family kinase signaling pathways, dasatinib's inhibition could result in reduced V1RJ3 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can alter the JNK signaling pathway. This could indirectly lead to decreased V1RJ3 activity if V1RJ3 is a downstream target of JNK signaling. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an AKT inhibitor that can indirectly affect V1RJ3 by inhibiting AKT, potentially leading to a reduction in V1RJ3 activity if AKT signaling modulates V1RJ3. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a RAF inhibitor that might lead to decreased V1RJ3 activity by obstructing the RAF/MEK/ERK signaling pathway if V1RJ3 is regulated by this pathway. | ||||||